Regulatory FDA seeks permanent future for rare pediatric priority review vouchers Pharmaceutical TechnologyThe rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.RegulatoryRare DiseaseRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Technology The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability. RegulatoryRare DiseaseRead full story Post navigation Previous: Syneron raises $150m for macrocyclics, and other financingsNext: Jeito Capital secures over $1.2bn for new biopharma investments Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
